Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
UBS
Medtronic
Cantor Fitzgerald
Argus Health
Express Scripts
Accenture
Teva
Johnson and Johnson

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,968,753

« Back to Dashboard

Which drugs does patent 8,968,753 protect, and when does it expire?

Patent 8,968,753 protects ZERBAXA and is included in one NDA.

This patent has fifteen patent family members in thirteen countries.
Summary for Patent: 8,968,753
Title:Ceftolozane-tazobactam pharmaceutical compositions
Abstract: Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam.
Inventor(s): Terracciano; Joseph (Concord, MA), Damour; Nicole Miller (Belmont, MA), Jiang; Chun (Hillsborough, CA), Fogliato; Giovanni (Barzana, IT), Donadelli; Giuseppe Alessandro (Casalpusterlengo, IT), Resemini; Dario (Milan, IT)
Assignee: Calixa Therapeutics, Inc. (Lexington, MA)
Application Number:14/285,185
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Process;

Drugs Protected by US Patent 8,968,753

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS ➤ Sign Up
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,968,753

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,044,485 Ceftolozane antibiotic compositions ➤ Sign Up
9,320,740 Ceftolozane-tazobactam pharmaceutical compositions ➤ Sign Up
9,872,906 Ceftolozane antibiotic compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,968,753

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Tunisia 2015000411 ➤ Sign Up
Peru 00482016 ➤ Sign Up
New Zealand 700372 ➤ Sign Up
Mexico 2015012833 ➤ Sign Up
South Korea 20150135363 ➤ Sign Up
Japan 2016517436 ➤ Sign Up
European Patent Office 3100732 ➤ Sign Up
European Patent Office 2893929 ➤ Sign Up
European Patent Office 2777705 ➤ Sign Up
Eurasian Patent Organization 201591712 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Baxter
Merck
Covington
Harvard Business School
McKinsey
Boehringer Ingelheim
US Army
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot